SIREN : 494595069
IKOS LAB is a French company founded 19 years ago, specialized in the sector Activités spécialisées, scientifiques et techniques diverses. Based in LEVALLOIS-PERRET (92300), this company of category ETI shows in 2024 a revenue of 3.3 M€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Data updated on 2026-05-02
Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy
| Indicator | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3 328 777 € | 3 799 353 € | 2 337 832 € | 1 514 146 € | 1 227 079 € | 1 158 164 € | 1 311 312 € | 1 020 782 € | 490 210 € | 329 805 € |
| Net income | 115 171 € | -90 730 € | 76 567 € | 11 866 € | 886 € | 93 346 € | 188 181 € | 301 167 € | 16 120 € | 69 443 € |
| EBITDA | 152 591 € | -89 505 € | 99 654 € | 14 935 € | 4 784 € | 79 352 € | 138 927 € | 247 007 € | -43 289 € | 10 559 € |
| Net margin | 3.5% | -2.4% | 3.3% | 0.8% | 0.1% | 8.1% | 14.4% | 29.5% | 3.3% | 21.1% |
In 2024, IKOS LAB achieves revenue of 3.3 M€. Over the period 2015-2024, the company shows strong growth with a CAGR (compound annual growth rate) of +29.3%. Significant drop of -12% vs 2023. After deducting consumption (0 €), gross margin stands at 3.3 M€, i.e. a rate of 100%. This ratio measures the ability to generate value from commercial activity. EBITDA (= Gross margin - Personnel expenses - Taxes) reaches 153 k€, representing 4.6% of revenue. Positive scissor effect: EBITDA margin improves by +6.9 pts, sign of improved operational efficiency. The operating margin remains fragile, requiring cost vigilance. Ultimately, net income (= EBIT +/- financial result +/- exceptional - corporate tax) amounts to 115 k€, i.e. 3.5% of revenue. This profit can be retained or distributed to shareholders.
3 328 777 €
3 328 777 €
152 591 €
150 789 €
115 171 €
4.6%
The debt ratio (= Financial debt / Equity x 100) stands at 182%. Critical situation: debt significantly exceeds equity, severely limiting borrowing capacity and exposing the company to default risk. Financial autonomy (= Equity / Total assets x 100) reaches 15%. Low autonomy: the company heavily depends on external financing (banks, suppliers). Debt repayment capacity (= Financial debt / Cash flow) indicates it would take 3.7 years of cash flow to repay all financial debt. This ratio remains within usual banking standards. Cash flow represents 3.4% of revenue. Cash flow measures resources generated by operations, available for investment and debt repayment.
182.273%
15.01%
3.445%
3.662
42.6%
In 2024, the debt ratio of IKOS LAB (182.27) ranks above the median of the sector. This ratio measures the weight of debt relative to equity. A reduction effort could improve financial strength.
In 2024, the financial autonomy of IKOS LAB (15.0%) ranks below the median of the sector. This ratio represents the share of equity in total financing. An improvement would strengthen the competitive position.
In 2024, the repayment capacity of IKOS LAB (3.66) ranks above the median of the sector. This ratio indicates the number of years needed to repay debt with cash flow. A reduction effort could improve financial strength.
The liquidity ratio (= Current assets / Current liabilities) stands at 172.19. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.
172.187
0.0
In 2024, the liquidity ratio of IKOS LAB (172.19) ranks below the median of the sector. This ratio measures the ability to cover short-term debt with current assets. An improvement would strengthen the competitive position.
In 2024, the interest coverage of IKOS LAB (0.0x) ranks below the median of the sector. This ratio indicates how many times operating income covers interest expenses. An improvement would strengthen the competitive position.
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 66 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 85 days. Favorable situation: supplier credit is longer than customer credit by 19 days. Overall, WCR represents 76 days of revenue, i.e. 706 k€ to permanently finance. Over 2015-2024, WCR increased by +353%, requiring additional financing.
706 333 €
66 j
85 j
0 j
76 j
Based on 98 transactions of similar company sales
(all years),
the value of IKOS LAB is estimated at
739 090 €
(range 207 562€ - 1 235 550€).
With an EBITDA of 152 591€, the sector multiple of 3.5x is applied.
The price/revenue ratio is 0.36x
(conservative valuation).
This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Medium reliability: estimate to be confirmed with in-depth analysis.
Ajustez les pondérations selon votre analyse
This estimate is based on the analysis of 98 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Compare IKOS LAB with other companies in the same sector:
Voir toutes les statistiques du secteur Activités spécialisées, scientifiques et techniques diverses
The revenue of IKOS LAB in 2024 is 3.3 M€.
Yes, IKOS LAB generated a net profit of 115 k€ in 2024.
The headquarters of IKOS LAB is located in LEVALLOIS-PERRET (92300), in the department Hauts-de-Seine.
The tax return of IKOS LAB is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
IKOS LAB operates in the sector Activités spécialisées, scientifiques et techniques diverses (NAF code 74.90B). See the 'Sector positioning' section above to compare the company with its competitors.